

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that Jiangsu Best New Medical Material Co., Ltd., a wholly-owned subsidiary in the Group, has developed a new product “Multi-layer co-extrusion bioprocessing films for single-use system in liquid dosing” (the “Product”) which has recently been put into industrial production and resulted in sales. Currently, it is the only domestic manufacturer of bioprocessing films in the PRC that can replace those imported.

The Product meets the relevant requirements under the USP Class VI of the United States Pharmacopoeia and the national standards of the PRC, is widely used in the fields of research and development and production of vaccines and biopharmaceuticals, and has broad market development prospects.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 27 May 2021

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.